Search Results - "Kowalski, Mark M."

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer by Kristeleit, Rebecca, Plummer, Ruth, Jones, Robert, Carter, Louise, Blagden, Sarah, Sarker, Debashis, Arkenau, Tobias, Evans, Thomas R. Jeffry, Danson, Sarah, Symeonides, Stefan N., Veal, Gareth J., Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai

“…Background This was a first-in-human Phase 1/2 open-label dose-escalation study of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737. Methods Patients with…”
Get full text

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer by Jones, Robert, Plummer, Ruth, Moreno, Victor, Carter, Louise, Roda, Desamparados, Garralda, Elena, Kristeleit, Rebecca, Sarker, Debashis, Arkenau, Tobias, Roxburgh, Patricia, Walter, Harriet S, Blagden, Sarah, Anthoney, Alan, Klencke, Barbara J, Kowalski, Mark M, Banerji, Udai

“…This was a Phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to establish…”
Get full text

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic by Verstovsek, Srdan, Chen, Chih-Cheng, Egyed, Miklós, Ellis, Martin, Fox, Laura, Goh, Yeow T, Gupta, Vikas, Harrison, Claire, Kiladjian, Jean-Jacques, Lazaroiu, Mihaela C, Mead, Adam, McLornan, Donal, McMullin, Mary F, Oh, Stephen T, Perkins, Andrew, Platzbecker, Uwe, Scheid, Christof, Vannucchi, Alessandro, Yoon, Sung-Soo, Kowalski, Mark M, Mesa, Ruben A

“…Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most…”
Get full text

Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers by Lissy, Michael, Stiff, Dwight D., Kowalski, Mark M., Moore, Keith A.

“…Abstract Objective: The clinical utility of diclofenac potassium, a commonly prescribed analgesic that provides mild to moderate pain relief, may be hindered…”
Get full text

418 - PHARMACOKINETICS OF EP-104IAR LONG-ACTING FLUTICASONE PROPIONATE FOR INTRA ARTICULAR INJECTION IN 163 SUBJECTS FROM SPRINGBOARD, A PHASE 2 STUDY IN KNEE OSTEOARTHRITIS by Helliwell, James A., Malone, Amanda, Kowalski, Mark M., Dobek, Christine, Peck, Vik, Loss, Troy

Get full text

PHARMACOKINETICS OF EP-104IAR LONG-ACTING FLUTICASONE PROPIONATE FOR INTRA ARTICULAR INJECTION IN 163 SUBJECTS FROM SPRINGBOARD, A PHASE 2 STUDY IN KNEE OSTEOARTHRITIS by Helliwell, James A., Malone, Amanda, Kowalski, Mark M., Dobek, Christine, Peck, Vik, Loss, Troy

Get full text

Sa1279 INITIAL RESULTS FROM RESOLVE, AN ONGOING PHASE 1B DOSEESCALATION STUDY OF EP-104GI (LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSION) FOR EOSINOPHILIC ESOPHAGITIS by Helliwell, James, Malone, Amanda, Kowalski, Mark M., Bredenoord, Arjan, Ko, Hin Hin, Nguyen, Nam Q., Dobek, Christine, Peck, Vik, Dellon, Evan S.

Get full text

EFFICACY OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS: PER-PROTOCOL ANALYSES FROM SPRINGBOARD, A PHASE 2, RANDOMIZED, 24-WEEK STUDY OF EP-104IAR (LONG-ACTING INTRA-ARTICULAR INJECTION OF FLUTICASONE PROPIONATE) by Helliwell, James A., Malone, Amanda, Kowalski, Mark M., Rovsing, Helene, Boll, Sidsel Lynggard, Bihlet, Asger R., Miller, Claire Prener, Mondragon, Alejandro Castillo, Li, Yanqi, Dobek, Christine, Peck, Vik, Wilmink, Mike, Conaghan, Philip, Simon, Lee S.

Get full text

063 - EFFICACY OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS: PER-PROTOCOL ANALYSES FROM SPRINGBOARD, A PHASE 2, RANDOMIZED, 24-WEEK STUDY OF EP-104IAR (LONG-ACTING INTRA-ARTICULAR INJECTION OF FLUTICASONE PROPIONATE) by Helliwell, James A., Malone, Amanda, Kowalski, Mark M., Rovsing, Helene, Boll, Sidsel Lynggard, Bihlet, Asger R., Miller, Claire Prener, Mondragon, Alejandro Castillo, Li, Yanqi, Dobek, Christine, Peck, Vik, Wilmink, Mike, Conaghan, Philip, Simon, Lee S.

Get full text

Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib by Mesa, Ruben A, Catalano, John, Cervantes, Francisco, Devos, Timothy, Gotlib, Jason, Kiladjian, Jean-Jacques, McLornan, Donal P., Shimoda, Kazuya, Coart, Elisabeth, D'Hollander, Koenraad, Donahue, Rafe, Kowalski, Mark M

“…Momelotinib (MMB) is a potent, selective, orally-bioavailable, small-molecule inhibitor of JAK1, JAK2 and ACVR1 being developed for the treatment of…”
Get full text

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients by Verstovsek, Srdan, Egyed, Miklos, Lech-Marańda, Ewa, Sacha, Tomasz, Dubruille, Viviane, Oh, Stephen T., Todorieva-Todorova, Doroteya, Passamonti, Francesco, Xicoy, Blanca, Andréasson, Björn, El Fassi, Daniel, Harrison, Claire, McLornan, Donal P., McMullin, Mary Frances Frances, Scheid, Christof, Severinsen, MArianne Tang, Kowalski, Mark M, Smith, Gregg, Mesa, Ruben

“…Introduction: Momelotinib (MMB) is a potent JAK1, JAK2 and ACVR1 inhibitor with clinical activity against the three hallmark features of myelofibrosis (MF),…”
Get full text

High level of surface CD4 prevents stable human immunodeficiency virus infection of T-cell transfectants by MARSHALL, W. L, DIAMOND, D. C, KOWALSKI, M. M, FINBERG, R. W

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers by Lissy, Michael, Stiff, Dwight D., Kowalski, Mark M., Moore, Keith A.

“…The clinical utility of diclofenac potassium, a commonly prescribed analgesic that provides mild to moderate pain relief, may be hindered by its delayed,…”
Get full text

Energy metabolism and Na+,K+ redistribution in human erythrocytes treated with lipopolysaccharide endotoxin by Wallas, C H, Warren, J R, Kowalski, M M

Get more information

Partial Purification of Rho(D) Antigen from Rh Positive and Negative Erythrocytes by Plapp, Fred V., Kowalski, Mark M., Tilzer, Lowell, Brown, Peggy J., Evans, James, Chiga, Masahiro

“…A rapid method is described for partial purification of Rho(D) antigen from sodium deoxycholate-solubilized erythrocyte membranes by affinity chromatography on…”
Get full text